These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Bevacizumab in thoracic oncology: results and practical aspects]. Dansin É; Cousin S; Lauridant G; Mennecier B Rev Pneumol Clin; 2013 Jun; 69(3):159-69. PubMed ID: 23597632 [TBL] [Abstract][Full Text] [Related]
10. Immuno-oncology drugs jostle for first-line setting. Mullard A Nat Rev Drug Discov; 2016 Nov; 15(11):738. PubMed ID: 27807351 [No Abstract] [Full Text] [Related]
11. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Kalemkerian G J Clin Oncol; 2005 Feb; 23(6):1325-6; author reply 1326-7. PubMed ID: 15718337 [No Abstract] [Full Text] [Related]
12. Advanced non-small cell lung cancer - treatment with Pembrolizumab. Silvinato A; Floriano I; Bernardo WM Rev Assoc Med Bras (1992); 2020 Mar; 66(3):256. PubMed ID: 32520141 [No Abstract] [Full Text] [Related]
13. Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer. Belani CP; Ramalingam S Clin Lung Cancer; 2005 Mar; 6(5):267-8. PubMed ID: 15845175 [No Abstract] [Full Text] [Related]
14. Advanced non-small cell lung cancer - Treatment with Pembrolizumab. Silvinato A; Floriano I; Bernardo WM Rev Assoc Med Bras (1992); 2019 Dec; 65(12):1423-1432. PubMed ID: 31994619 [No Abstract] [Full Text] [Related]
15. Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer? Mok TSK; Loong HH Lancet; 2016 Apr; 387(10027):1488-1490. PubMed ID: 26712085 [No Abstract] [Full Text] [Related]
16. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective. Girard N Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421 [TBL] [Abstract][Full Text] [Related]
18. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). Mueller E Lung Cancer; 2010 Aug; 69 Suppl 1():S1-3. PubMed ID: 20727456 [No Abstract] [Full Text] [Related]
19. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer. Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in lung cancer. Wang Y; Deng G; Liu X; Cho WC Expert Opin Biol Ther; 2013 Feb; 13(2):209-26. PubMed ID: 23240766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]